A natural experiment on the effect of herpes zoster vaccination on dementia
Neurotropic herpesviruses may be implicated in the development of dementia<sup>1-5</sup>. Moreover, vaccines may have important off-target immunological effects<sup>6-9</sup>. Here we aim to determine the effect of live-attenuated herpes zoster vaccination on the occurrence of dementia diagnoses. To provide causal as opposed to correlational evidence, we take advantage of the fact that, in Wales, eligibility for the zoster vaccine was determined on the basis of an individual's exact date of birth. Those born before 2 September 1933 were ineligible and remained ineligible for life, whereas those born on or after 2 September 1933 were eligible for at least 1 year to receive the vaccine. Using large-scale electronic health record data, we first show that the percentage of adults who received the vaccine increased from 0.01% among patients who were merely 1 week too old to be eligible, to 47.2% among those who were just 1 week younger. Apart from this large difference in the probability of ever receiving the zoster vaccine, individuals born just 1 week before 2 September 1933 are unlikely to differ systematically from those born 1 week later. Using these comparison groups in a regression discontinuity design, we show that receiving the zoster vaccine reduced the probability of a new dementia diagnosis over a follow-up period of 7 years by 3.5 percentage points (95% confidence interval (CI) = 0.6-7.1, P = 0.019), corresponding to a 20.0% (95% CI = 6.5-33.4) relative reduction. This protective effect was stronger among women than men. We successfully confirm our findings in a different population (England and Wales's combined population), with a different type of data (death certificates) and using an outcome (deaths with dementia as primary cause) that is closely related to dementia, but less reliant on a timely diagnosis of dementia by the healthcare system<sup>10</sup>. Through the use of a unique natural experiment, this study provides evidence of a dementia-preventing or dementia-delaying effect from zoster vaccination that is less vulnerable to confounding and bias than the existing associational evidence.
Authors
- Markus Eyting (ORCID: https://orcid.org/0000-0002-4228-2646)
- Pascal Geldsetzer (ORCID: https://orcid.org/0000-0002-8878-5505)
- Felix Michalik (ORCID: https://orcid.org/0000-0001-5589-5700)
- Seung‐hun Chung (ORCID: https://orcid.org/0000-0002-0799-2183)
- Simon Heß (ORCID: https://orcid.org/0000-0003-1776-0930)
- Min Xie (ORCID: https://orcid.org/0000-0003-4835-7060)
Institutions
- Vienna University of Economics and Business (AT)
- Neurosciences Institute (US)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Stanford Health Care (US)
- Chan Zuckerberg Initiative (United States) (US)
- Leibniz Institute for Financial Research SAFE (DE)
- Stanford University (US)
Publication Details
- Journal
- Nature
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1038/s41586-025-08800-x
- Citations
- 135
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 181.46
Funders
- Wu Tsai Neurosciences Institute, Stanford University
- National Institute of Allergy and Infectious Diseases